Zhejiang Jiuzhou Pharmaceutical Co Ltd banner
Z

Zhejiang Jiuzhou Pharmaceutical Co Ltd
SSE:603456

Watchlist Manager
Zhejiang Jiuzhou Pharmaceutical Co Ltd
SSE:603456
Watchlist
Price: 17.66 CNY -0.9% Market Closed
Market Cap: ¥15.7B

Net Margin

13.5%
Current
Declining
by 2.4%
vs 3-y average of 15.9%

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
13.5%
=
Net Income
¥722.9m
/
Revenue
¥5.4B

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
13.5%
=
Net Income
¥722.9m
/
Revenue
¥5.4B

Peer Comparison

Country Company Market Cap Net
Margin
CN
Zhejiang Jiuzhou Pharmaceutical Co Ltd
SSE:603456
15.7B CNY
Loading...
US
Eli Lilly and Co
NYSE:LLY
987.9B USD
Loading...
US
Johnson & Johnson
NYSE:JNJ
596.5B USD
Loading...
CH
Roche Holding AG
SIX:ROG
293B CHF
Loading...
CH
Novartis AG
SIX:NOVN
249.7B CHF
Loading...
UK
AstraZeneca PLC
LSE:AZN
240.5B GBP
Loading...
US
Merck & Co Inc
NYSE:MRK
307.4B USD
Loading...
IE
Endo International PLC
LSE:0Y5F
218B USD
Loading...
DK
Novo Nordisk A/S
CSE:NOVO B
1.1T DKK
Loading...
US
Pfizer Inc
NYSE:PFE
156.9B USD
Loading...
US
Bristol-Myers Squibb Co
NYSE:BMY
125.6B USD
Loading...

Market Distribution

Higher than 79% of companies in China
Percentile
79th
Based on 8 721 companies
79th percentile
13.5%
Low
-416 945.9% — -1.5%
Typical Range
-1.5% — 8.9%
High
8.9% — 17 382.1%
Distribution Statistics
China
Min -416 945.9%
30th Percentile -1.5%
Median 3.5%
70th Percentile 8.9%
Max 17 382.1%

Zhejiang Jiuzhou Pharmaceutical Co Ltd
Glance View

Market Cap
15.7B CNY
Industry
Pharmaceuticals

Founded in 1973, Zhejiang Jiuzhou Pharmaceutical Co. Ltd. has steadily navigated the evolving tides of the global pharmaceutical industry with a compelling blend of innovation and traditional business acumen. Rooted in China's dynamic Zhejiang province, the company initially focused on manufacturing basic pharmaceutical intermediates. Over the years, it strategically expanded its operations, becoming a key player in both the Active Pharmaceutical Ingredients (APIs) and Contract Development and Manufacturing Organization (CDMO) sectors. This dual focus has allowed Jiuzhou Pharmaceutical to innovate and offer comprehensive services, ranging from drug development to commercial manufacturing, effectively appealing to a broad range of customers including some of the world's leading pharmaceutical companies. At the heart of Jiuzhou Pharmaceutical's success lies its commitment to research and development, a cornerstone that supports its diversification strategy. The company leverages its extensive expertise and cutting-edge technology to improve existing drugs while also participating in the development of new, patented pharmaceuticals. By fostering strong partnerships with global pharmaceutical giants, Jiuzhou effectively integrates itself into the larger pharmaceutical ecosystem, providing customized solutions that resonate with market demand. This business model not only reinforces its financial growth but also establishes Zhejiang Jiuzhou as an indispensable contributor to advancements in medicine, continually enhancing its reputation on the international stage.

Zhejiang Jiuzhou Pharmaceutical Co Ltd Intrinsic Value
HIDDEN
Show
What is Net Margin?
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
How is Net Margin calculated?

Net Margin is calculated by dividing the Net Income by the Revenue.

Net Margin
13.5%
=
Net Income
¥722.9m
/
Revenue
¥5.4B
What is Zhejiang Jiuzhou Pharmaceutical Co Ltd's current Net Margin?

The current Net Margin for Zhejiang Jiuzhou Pharmaceutical Co Ltd is 13.5%, which is below its 3-year median of 15.9%.

How has Net Margin changed over time?

Over the last 3 years, Zhejiang Jiuzhou Pharmaceutical Co Ltd’s Net Margin has decreased from 16.6% to 13.5%. During this period, it reached a low of 11.7% on Dec 31, 2024 and a high of 20.3% on Sep 30, 2023.

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett